US ANDA Approvals Soar, But Does FDA Need To Do More?
This article was originally published in PharmAsia News
Executive Summary
An industry consultant suggests that the US FDA’s Office of Generic Drugs has to boost its approval volume even higher if it wants to cut its increasing workload.